Biocon Limited · NSE:BIOCON
Biocon — Investor Presentation (February 2016)
30 slides from Biocon's investor presentation, February 2016
Slide 1: Investor Presentation
Investor Presentation February 2016 BSE: 532523 │ NSE: BIOCON │ REUTERS: BION.NS │ BLOOMBERG: BIOS IN │ WWW.BIOCON.COM
Slide 2: Safe Harbor
Safe Harbor Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.
Slide 3: Agenda
Agenda Biocon: Who are we? Highlights • Business Highlights • Financial Highlights Growth Segments • Small Molecules • Biosimilars • Branded Formulations • Novel Molecules • Research Services - Syngene Financials Outlook 3
Slide 4: Biocon: Who are we?
Biocon: Who are we? 4
Slide 5: Biocon: Asia’s Leading Biopharma Company
Biocon: Asia’s Leading Biopharma Company Our Vision To enhance global healthcare through innovative and affordable biopharmaceuticals for patients, partners and healthcare systems across the globe 5
Slide 6: The Biocon Journey: A continuous evolution
The Biocon Journey: A continuous evolution Successful IPO, Biocon listed in India Poised for global impact Building the India Business An Enzymes Company with Biosimilar insulins and expertise in biologics People: 250 & Antibodies Revenue: ₹ 11,940 Million Revenue: ₹ 320 Million Target US$1bn in sal
Slide 7: Evolution of Key Innovations: Making a Difference
Evolution of Key Innovations: Making a Difference 1979 - First Indian company to manufacture and export enzymes to US and Europe 2001 - First Indian company to be approved by US FDA for the manufacture of lovastatin from solid state fermentation 2004 - First company worldwide to commercialize generi
Slide 8: YTD Business Highlights
YTD Business Highlights Biocon successfully listed Syngene, its Biocon’s Research Services subsidiary IPO oversubscribed 31 times, market capitalization* of INR 76.6 bn Listed on NSE and BSE on August 11, 2015 Biosimilar programs accelerating through the clinic Biocon continues to cross critical mil
Slide 9: Financial Highlights – Q3 & 9M FY16
Financial Highlights – Q3 & 9M FY16 All Figures in ₹ Million except % Particulars Q3 FY16 Q3 FY15 Growth 9M FY16 9MFY15 Growth Revenue 8,561 7,790 10% 25,704* 22,883 12% EBITDA 2,088 1,697 23% 6,667 5,483 22% Net Profit 1,030 909 13% 5,352** 2,959 81% R&D Expenses 679 467 45% 1,752 1,128 55% in P&L
Slide 10: Segmental Sales – Q3 & 9M FY16
Segmental Sales – Q3 & 9M FY16 All Figures in ₹ Million except % Particulars Q3 FY16 Q3 FY15 Growth 9M FY16 9M FY15 Growth Biopharma 4,536 4,366 4% 14,007* 13,137 7% Branded 1,045 1,047 0% 3,357 3,312 1% Formulations Research 2,701 2,196 23% 7,444 5,841 27% Services Total 8,282 7,609 9% 24,808 22,29
Slide 11: Business Segments
Thy oO Business Segments
Slide 12: Growth Verticals: Aligned with Shifting Paradigms
Growth Verticals: Aligned with Shifting Paradigms 1. (a) APIs and (b) Generic Formulations Small Molecules 2. Insulins, 5. Integrated MAbs & Other offerings Research Biosimilars (Biologics & Biologics Services (Syngene) g. Insulins) Growth Verticals 4. Unlock Value Novel Branded 3. India-centric Mol
Slide 13: 1a. Small Molecule APIs
1a. Small Molecule APIs Product Portfolio which leverages our core fermentation capabilities and have a high degree of complexity. Early mover in niche products at commercial scale. One of the largest producers of various fermentation based statins and immunosuppressant API in India and across the g
Slide 14: 1b. Small Molecules Generics Formulations
1b. Small Molecules Generics Formulations Nascent pipeline To file ~20-25 dossiers in the next few years Pipeline includes solid oral & parenteral products in both potent & non-potent categories of compounds. Product pipeline comprises of ‘difficult to make,’ technology intensive molecules for emerg
Slide 15: 2. Biosimilars
2. Biosimilars Amongst the largest portfolio of Biosimilars globally straddling human insulin/insulin analogs, monoclonal antibodies and other biologics. Addressable market size: ~US$60 Billion Strong scientific and technical capabilities and manufacturing expertise to address global opportunities.
Slide 16: Biosimilars: Growth through partnership
Biosimilars: Growth through partnership BIOCON MYLAN • Global-scale, complex biologics • Strength in Regulatory/ filings manufacturing capabilities strategy • Facilities accredited by • Strong commercialization international regulatory agencies capability in US and EU. • Decade-long experience & • M
Slide 17: Biosimilars: Insulins Pipeline
Biosimilars: Insulins Pipeline Market Size* Molecule Type Status (US$ bn) Rh Insulin Recombinant Human Insulin EU Phase III complete 3.1 Glargine Long Acting Basal Insulin Global Phase III 7.1 Aspart Rapid Acting Insulin Analog Preclinical/Scale Up 4.7 Lispro Rapid Acting Insulin Analog Preclinical/
Slide 18: Biosimilars: MAbs & Biologics Pipeline
Biosimilars: MAbs & Biologics Pipeline Market Size* Molecule Indication Status (US$ bn) Adalimumab Chronic Plaque Psoriasis Global Phase III 14.0 Trastuzumab mBreast Cancer Global Phase III 6.8 Chemo-induced Pegfilgrastim Global Phase III 4.7 Neutropenia Bevacizumab mColorectal Cancer EU Phase 1, Ro
Slide 19: Biosimilars: Biocon well placed in the Competitive Landscape
Biosimilars: Biocon well placed in the Competitive Landscape Patent 2014 Top 10 Biologics 1 Company Term – Sales Biosimilar Development Pipeline* US (US$ bn) Pre-Clinical Phase I Phase III/Filed Humira (adalimumab) AbbVie 2016 11.8 Lantus (insulin glargine) Sanofi 2015 10.3 Enbrel (etanercept) Amgen
Slide 20: Biosimilars Manufacturing: Building Global Scale
Biosimilars Manufacturing: Building Global Scale Biocon Malaysia: Asia’s largest integrated insulins manufacturing facility Biocon’s First Manufacturing expansion overseas in Iskandar, Johor. Capital Investment of over US$200mn in the first phase. Emerging market filings planned for FY17. Disposable
Slide 21: 3. Branded Formulations: Introduction
3. Branded Formulations: Introduction • Presently an India focused Specialty Business with Regional Ambitions • Organized into 5 key divisions around chronic therapy areas • Strategy focused around biologics and differentiated products as anchor brands. • Portfolio highlights: • Insugen® & Basalog®:
Slide 22: 4. Novel Molecules
4. Novel Molecules • Multiple sets of studies completed to establish Post Prandial Insulin Tregopil glycemic control. First-in-Class Oral Prandial Insulin • Sizeable global opportunity Itolizumab • Commercialized in India for Psoriasis. LEAD PROGRAMS Novel, humanized antibody directed at CD6 • Studi
Slide 23: 5. Syngene (Research Services Business)
5. Syngene (Research Services Business) Global High Growth CRO Company Attractive Blue Chip Customer Base • One of the leading India-based contract • Highly successful track-record in research organizations (CRO) molecule development • Integrated discovery and development • Client base includes 8 of
Slide 24: Syngene: Value unlocking through a successful IPO
Syngene: Value unlocking through a successful IPO • Subscription: IPO Oversubscribed 31x • Allotment Price: INR 250 (Implied market cap US$770mn) • Listing Price: INR 295 • Closing on Listing Day (August 11, 2015): INR 310 (25% premium) • Price Range since listing: INR.295-436 • Current Market Cap:
Slide 25: Five Year Financials
nO VecO Five Year Financials SOND
Slide 26: Consolidated Financial Performance (FY11-15)
Consolidated Financial Performance (FY11-15) All Figures in ₹ Million except EPS Business Segment FY11 FY12 FY13 FY14 FY15 Biopharmaceuticals 14,866 16,764 18,705 21,382 22,367 - Biopharma 13,023 14,170 15,231 17,468 18,071 - Branded Formulations 1,863 2,594 3,474 3,914 4,296 Contract Research 3,177
Slide 27: Appendix
— 2 YS po Appendix SOND
Slide 28: Aspiring for $1 Billion in Revenues by FY 2018-19
Aspiring for $1 Billion in Revenues by FY 2018-19 Key Focus Areas o Small Molecules & Generic Formulations- Improved product mix incl. ANDAs o Biosimilars - Meaningful near term growth to be driven 25% by emerging markets, ramp up post developed market entry 30% o Branded Formulations –Strategy focu
Slide 29: Shareholding Pattern & Business Holdings
Shareholding Pattern & Business Holdings* BIOPHARMA SUBSIDIARIES Biocon Research, India | 100% R&D- Novel Molecules & Biosimilars Biocon Pharma, India | 100% Manufacturing - Generic Formulations Biocon Pharma Inc., USA | 100% Step Down Subsidiary ~61% | Promoters Biocon Sdn. Bhd, Malaysia | 100% ~ 2
Slide 30: For more information, please visit www.biocon.com
For more information, please visit www.biocon.com Investor Relations contact: Saurabh Paliwal Tel : +91 80 6775 2040 Email: saurabh.paliwal@biocon.com 30